RxDoctor Payments Data

Joel Kurtz, MD

Gastroenterology · Lakewood, NJNPI 1205882578

Payments from drug & device makers

$576in general payments, 2019–2025

Across 35 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$138
  • AbbVie$119
  • Takeda Pharmaceuticals U.S.A., Inc.$55
  • Pfizer$52
  • Johnson & Johnson$39
  • Shionogi Inc$31
  • plus $142 from 8 others

What the payments were for

  • Food & beverage$576100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$576 in reported general payments places this provider in the 20th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$60,356
Medicare patients
209
Services billed
431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin43$120,517
CreonLipase/Protease/Amylase38$66,136
LinzessLinaclotide25$19,466
Mesalamine42$17,180
Dexlansoprazole DrDexlansoprazole21$5,936
Pantoprazole Sodium205$1,873
Balsalazide Disodium12$1,804
Sucralfate16$1,518
Famotidine97$1,425
Lubiprostone18$1,242
Esomeprazole Magnesium29$963
Colestipol Hcl12$904
Omeprazole82$555
Dicyclomine Hcl14$415
Ondansetron OdtOndansetron11$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$138$120,51743 claims
AbbVieCreon, Linzess$119$85,60263 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Lakewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →